Type Public limited company Industry Healthcare Headquarters Republic of Ireland Net income 264 million USD (2014) | Traded as NASDAQ: HZNP Website www.horizonpharma.com Founded 2005 | |
Key people Timothy P. Walbert (Chairman, President & CEO)
Paul W. Hoelscher (CFO)
Robert F. Carey (CBO)
Jeffrey W. Sherman, M.D. (CMO) Stock price HZNP (NASDAQ) US$ 15.27 +0.05 (+0.30%)14 Mar, 2:46 PM GMT-4 - Disclaimer CEO Timothy P. Walbert (Jun 2008–) Subsidiaries NASDAQ:HZNP, Raptor Pharmaceuticals | ||
Horizon Pharma Public Limited Company (NASDAQ: HZNP) is a specialty pharmaceutical company that develops and markets medicine through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The company focuses on developing treatments for arthritis, pain and inflammatory diseases. Horizon's product portfolio includes Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), and Rayos/Lodotra (prednisone). In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Business
The company lead product base includes DUEXIS and RAYOS. Outside the United States, RAYOS is also known as LODOTRA.
The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named “Connect to Protect” which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers.
In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million.
In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.
In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizons orphan disease drug portfolio. In December, the company acquire Crealta Holdings for $510 million.
In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio.